Stem cell-derived organoids have emerged as a cutting-edge technology with immense potential in revolutionizing disease modeling and drug screening processes. These miniature 3D tissue structures, resembling organ-specific architecture and functionality, hold promise in providing more accurate representations of human physiology compared to traditional cell cultures. In the realm of biomedical research, the utilization of organoids offers a platform for studying disease mechanisms, testing drug efficacy, and advancing personalized medicine approaches. However, despite the opportunities presented by organoid technology, various challenges persist in their implementation, ranging from mimicking complex in vivo environments to ensuring reproducibility. This article delves into assessing the challenges and opportunities of stem cell-derived organoids in disease modeling and drug screening, exploring the advancements, case studies, and ethical considerations shaping this rapidly evolving field.
